News

Currently, AYX1 is being developed for reduction of acute post-surgical pain and prevention of the transition to persistent or chronic pain with a single administration at the time

SMC has issued its final advice, following a Health Technology Appraisal accepting linagliptin as an additional treatment option for these patients in combination with insulin with or without

The company’s latest report* states that while this growth will be primarily driven by the potential introduction of four late-stage pipeline agents, consisting of reformulations of existing therapies

Both the parties will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators to treat immunological diseases including lupus, Sjögren’s Syndrome, inflammatory bowel disease and

The summary will be presented today at 10:15 a.m. EDT at the 4th Joint International Spinal Cord Society (ISCoS) and American Spinal Injury Association (ASIA) meeting being held

The Company’s legal counsel, Ferrere Abogados of Montevideo, Uruguay, represented the Company throughout the licensing process. The Company’s license is provisional and subject to the Company submitting additional

Moreover, stroke recovery was improved 2-fold in patients receiving THR-18, as judged by clinical outcome measures, 30 days following stroke. THR-18 is a novel drug-candidate designed to neutralize

Under the agreement, Catalent will provide all cell line engineering, process development and clinical Good Manufacturing Practices (cGMP) biomanufacturing activities necessary for the rapid development of a high

The company said that the results support a biologics license application (BLA) for US approval of the vaccine. A total of 4,000 vaccinia-naïve subjects were involved in the